证券代码：300119 证券简称：瑞普生物 公告编号：2020-077 天津瑞普生物技术股份有限公司 关于举行投资者网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天津瑞普生物技术股份有限公司（以下简称"公司"）已于 2020 年 4 月 2 日发布了 2019 年年度报告。为便于广大投资者更深入全面地了解公司情况，公 司定于 2020 年 6 月 10 日（周三）15:00-16:30 在全景网举办 2019 年度天津辖 区网上集体接待日活动。 本次活动将采用网络远程的方式举行，投资者可登录"全景•路演天下" （http://rs.p5w.net）参与本次互动交流。出席本次"天津辖区网上集体接待 日"的人员有：公司董事长、总经理李守军先生，董事会秘书徐健女士。 欢迎广大投资者积极参与。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二〇年五月二十九日 ...

天津瑞普生物技术股份有限公司 2020 年第一季度报告全文 天津瑞普生物技术股份有限公司 2020 年第一季度报告 2020-060 2020 年 04 月 1 天津瑞普生物技术股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李守军、主管会计工作负责人李守军及会计机构负责人(会计主 管人员)王永桢声明：保证季度报告中财务报表的真实、准确、完整。 2 天津瑞普生物技术股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|--- ...

Financial Performance - The company's operating revenue for 2019 was ¥1,466,580,504.34, representing a 23.26% increase compared to ¥1,189,866,012.40 in 2018[17]. - The net profit attributable to shareholders for 2019 was ¥194,359,933.86, a significant increase of 63.36% from ¥118,978,853.68 in 2018[17]. - The net cash flow from operating activities reached ¥383,608,950.31, marking a 119.35% increase from ¥174,881,770.06 in 2018[17]. - The basic earnings per share for 2019 was ¥0.4894, up 66.41% from ¥0.2941 in 2018[17]. - Total assets at the end of 2019 amounted to ¥3,563,250,715.37, an 18.84% increase from ¥2,998,445,848.76 at the end of 2018[17]. - The company reported a weighted average return on equity of 9.41% for 2019, up from 6.02% in 2018[17]. - The net profit excluding non-recurring gains and losses for 2019 was ¥108,868,030.12, an increase of 8.32% from ¥100,504,372.87 in 2018[17]. - The total profit amounted to CNY 25,991,640, representing a 60.49% increase year-on-year[52]. - Net profit attributable to shareholders was CNY 19,435,990, up 63.36% from the previous year[52]. - The company achieved a total revenue of 3,351,206 RMB for the year 2019[184]. Dividend Distribution - The company reported a profit distribution plan, proposing a cash dividend of 2.5 RMB per 10 shares based on a total of 400,356,062 shares[6]. - The cash dividend distribution represents 100% of the total profit distribution for the year[122]. - The company has maintained a stable and continuous profit distribution policy, prioritizing cash dividends[119]. - The cash dividend will be distributed within two months after the shareholders' meeting[120]. - The company reported a cash dividend of 100,089,015.50 in 2019, representing 51.50% of the net profit attributable to ordinary shareholders[124]. - The total cash dividend for 2019, including other methods, amounted to 200,539,840.08, which is 103.18% of the net profit attributable to ordinary shareholders[124]. - The average distributable profit over the last three years is 30% of the total distributable profit[119]. Research and Development - The company has a strong commitment to research and development in new technologies and products[11]. - The company has established a cross-departmental collaborative innovation system with a focus on market needs, supported by a 300-person innovation team led by industry experts[34]. - The company has developed over 280 animal products, including nearly 170 chemical drugs, over 60 biological products, and 30 feed additives, making it one of the most comprehensive veterinary drug companies in China[36]. - The company achieved a research and development investment of approximately ¥114.36 million in 2019, accounting for 7.80% of its operating revenue[72]. - The company is focused on enhancing its market competitiveness through the development of upgraded vaccine products for swine diseases[71]. - The company is actively developing vaccines for African swine fever and foot-and-mouth disease, collaborating with various research institutions to address major epidemic threats[42]. - The company launched the world's first dual-subunit vaccine for pig streptococcus and actinobacillus pleuropneumonia, achieving international leading standards[41]. - The company obtained 21 veterinary product approval numbers and 19 patents during the reporting period[65]. Market Expansion and Strategy - The company is actively expanding its market presence through strategic partnerships and acquisitions[11]. - The company is transitioning from a sales-oriented model to a service-oriented model, focusing on prevention and health care solutions for livestock[29]. - The company is focused on market expansion strategies, particularly in the veterinary and animal nutrition sectors[67]. - The company anticipates a rebound in pork production and continuous growth in poultry production in 2020, driven by increased intensive farming and higher management standards[104]. - The company plans to strengthen its R&D capabilities and develop high-efficiency, high-quality, safe, and environmentally friendly animal health products[106]. - The company aims to improve operational efficiency through strategic partnerships and potential acquisitions[67]. Risks and Challenges - The company faces risks including human resources, product development, and significant accounts receivable[6]. - The ongoing African swine fever epidemic is reshaping the livestock and veterinary medicine industry, leading to increased demand for high-quality veterinary products[31]. - The company faces risks related to long product development cycles and regulatory approvals, which may impact the timely launch of new veterinary drugs[112]. - The company is actively managing accounts receivable risks by implementing a tiered credit management policy, ensuring most customer debts remain within normal credit periods[112]. Corporate Governance and Compliance - The company has confirmed that there are no competing businesses controlled by major shareholders that could pose a threat to its operations[127]. - The company has made commitments to avoid related party transactions and ensure no fund occupation by major shareholders[127]. - The company has maintained a stable governance structure with no significant changes in its board composition[195]. - The company has not reported any violations of commitments related to the issuance and underwriting management regulations during the reporting period[128]. - The company has established a special account for the management of raised funds, ensuring strict compliance with relevant regulations[130]. Production and Quality Control - The company operates 79 production lines, including 31 GMP production lines for drug formulations and 32 GMP lines for biological products, ensuring high production capacity and quality[36]. - The company maintains a product quality inspection pass rate that ranks among the top in the industry, adhering to a quality standard 10% higher than national standards[36]. - The company has completed small-scale production processes for several new veterinary raw materials, indicating progress in its product development pipeline[71]. Shareholder Information - The total number of shares before the change was 404,493,463, with 52.38% being restricted shares[170]. - The company repurchased a total of 9,528,401 shares, accounting for approximately 2.36% of the total share capital before the repurchase[176]. - The total number of shares held by major shareholders at the end of the reporting period was 211,890,996, with a decrease of 11,180,569 shares during the period[180]. - The number of shareholders holding shares with voting rights increased from 23,369 to 24,107 during the reporting period[182]. Environmental and Social Responsibility - The company has completed the construction of pollution prevention facilities, which are operating normally[163]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[163]. - The company has established an environmental self-monitoring plan and has commissioned a third party for regular pollutant emission monitoring[166].

Financial Performance - Operating revenue for the period reached CNY 379,672,503.23, representing a 29.40% increase year-over-year[12] - Net profit attributable to shareholders rose by 55.74% to CNY 58,311,268.02 for the quarter[12] - The net profit after deducting non-recurring gains and losses increased by 58.91% to CNY 52,006,587.11[12] - Basic earnings per share increased by 55.72% to CNY 0.1442[12] - The weighted average return on net assets improved to 2.97%, up from 1.08% in the previous year[12] - The company reported a net cash flow from operating activities of CNY 170,176,231.25, a 109.41% increase year-to-date[12] - The company reported a net profit of CNY 66,662,720.22 for the quarter, reflecting a significant increase compared to the previous year's profit[52] - The net profit for the third quarter reached CNY 68,099,325.44, representing a 60.5% increase from CNY 42,511,518.97 year-over-year[54] - The total profit for the third quarter was CNY 80,370,811.18, up from CNY 47,351,306.71, indicating a growth of 69.9% year-over-year[54] Shareholder Information - The total number of shareholders at the end of the reporting period was 29,875[16] - The largest shareholder, Li Shoujun, holds 42.23% of the shares, amounting to 170,809,411 shares[16] - The company repurchased a total of 9,528,401 shares, accounting for approximately 2.36% of the total share capital before the repurchase plan, with a total transaction amount of ¥100,450,824.58 (excluding transaction fees) [29] - The maximum transaction price during the share repurchase was ¥13.74 per share, while the minimum was ¥7.57 per share [29] - The company issued 5,391,000 A-shares at a price of ¥7.08 per share to 178 employees as part of the 2019 restricted stock incentive plan [30] - The shares granted under the incentive plan were subject to limited sale conditions and were listed on June 26, 2019 [30] - The company maintains a continuous and stable profit distribution policy, prioritizing cash dividends [31] - The profit distribution policy aims to balance the long-term interests of the company and the overall interests of all shareholders [31] Assets and Liabilities - Total assets increased by 6.02% to CNY 3,178,880,712.35 compared to the end of the previous year[12] - The company's current assets totaled CNY 1,480,185,804.06, up from CNY 1,361,366,777.48 in the previous year[43] - The company’s non-current assets totaled CNY 1,698,694,908.29, slightly up from CNY 1,637,079,071.28[43] - Total liabilities increased to CNY 834,948,505.51 from CNY 670,880,425.11 year-on-year[49] - Current liabilities totaled CNY 665,462,930.52, with short-term borrowings at CNY 350,557,500.00[76] - The company has a total of CNY 744,032,870.06 in liabilities, with non-current liabilities at CNY 78,569,939.54[76] - The total owner's equity attributable to the parent company was CNY 2,010,171,830.02, reflecting strong financial health[77] Research and Development - The company filed for several new patents and trademarks, enhancing its intellectual property portfolio during the reporting period[26] - The company is committed to advancing its research and development efforts to meet the evolving needs of the veterinary market[27] - Research and development expenses for the quarter were CNY 23,895,772.91, compared to CNY 19,015,519.91 in the previous year[52] - The company is focused on addressing antibiotic resistance issues in veterinary medicine through innovative product development [28] - Research and development expenses for Q3 2019 amounted to CNY 20,612,900.25, up from CNY 18,903,360.11 in the same quarter last year, indicating a growth of 6.4%[64] Product Development and Market Position - The company has obtained the "New Veterinary Drug Registration Certificate" for the H5 subtype avian influenza DNA vaccine, marking it as a first-class new veterinary drug currently under monitoring[27] - The company has also received the "New Veterinary Drug Registration Certificate" for the inactivated Newcastle disease vaccine (A-VII strain), which is now a first-class new veterinary drug under monitoring[27] - The company is in the application stage for production approval of a dual-subunit vaccine for swine streptococcus and hemophilus diseases, which is an upgrade to existing inactivated vaccines[27] - The company is developing a recombinant canine alpha-interferon product, which is currently in the new veterinary drug certification phase[27] - The company is focusing on expanding its product line to include vaccines that address current global strains of Newcastle disease, filling a significant market gap[27] - The company emphasizes the importance of its new products in enhancing biosecurity and disease prevention in poultry farming, which has both social and economic significance[27] - The company has made progress in the development of a new vaccine that combines the advantages of long immune response time and high biosafety for H5 subtype avian influenza[27] Cash Flow and Investment Activities - The cash inflow from operating activities was CNY 1,023,353,333.86, compared to CNY 842,303,990.90 in the previous year, representing a growth of 21.5%[67] - The company reported a total cash inflow from operating activities of CNY 398,030,250.65, compared to CNY 319,124,116.32 in the previous year, marking a growth of 24.7%[70] - Total cash inflow from investment activities was CNY 941,177,273.43, down from CNY 1,195,964,433.42 year-over-year, indicating a decrease of approximately 21.3%[68] - The net cash flow from investment activities was negative at CNY -189,095,558.79, compared to CNY -88,051,947.01 in the previous year, reflecting a worsening of 114%[68] - Cash inflow from financing activities totaled CNY 554,168,280.00, an increase of 41.2% from CNY 392,557,500.00 in the same quarter last year[69] - The net cash flow from financing activities was CNY -8,114,005.98, an improvement from CNY -65,014,156.58 year-over-year[69]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 300 million RMB for the first half of 2019, representing a year-on-year growth of 25%[17]. - Total revenue for the reporting period was ¥653,450,036.25, an increase of 12.05% compared to the same period last year[25]. - Net profit attributable to shareholders was ¥86,341,894.73, representing a growth of 26.04% year-over-year[25]. - Total profit reached 120.16 million yuan, reflecting a year-on-year growth of 27.75%[58]. - The company achieved operating revenue of 653.45 million yuan, a year-on-year increase of 12.05%[58]. - The company’s cash flow from operating activities was 76.99 million yuan, indicating a healthy financial status[58]. - The company reported a net cash flow from operating activities of RMB 76.99 million, a significant increase of 114.37% compared to the previous year, primarily due to increased sales collections[88]. Market Expansion and Product Development - The company has set a revenue guidance of 600 million RMB for the full year 2019, indicating a projected growth of 20%[17]. - New product development includes the launch of two innovative veterinary vaccines, expected to contribute an additional 50 million RMB in revenue by the end of the year[17]. - The company is actively pursuing market expansion, targeting a 30% increase in market share in the animal health sector over the next two years[17]. - The company continues to focus on the animal health industry, with a commitment to developing high-quality veterinary products and expanding its product range[35]. - The company has developed over 280 animal products, including nearly 170 chemical drugs and 60 biological products, establishing a strong competitive advantage in the veterinary medicine industry[50]. - The company launched a trivalent inactivated vaccine for avian influenza (H5+H7) in February 2019, leading to a significant increase in sales volume and price[57]. - The company is in the process of obtaining production qualifications for a new DNA vaccine for H5 subtype avian influenza, which has high technological content and fills an international gap[69]. Research and Development - The company has initiated a strategic acquisition of a smaller biotech firm, which is expected to enhance its R&D capabilities and product offerings[17]. - The company has established partnerships with three leading universities to enhance its research initiatives and drive innovation in animal health products[17]. - The company has a professional R&D team of nearly 300 members, leading the industry in scale and innovation capabilities[48]. - The company’s R&D investment increased by 13.74% to RMB 47.74 million, indicating a commitment to innovation and product development[88]. - The company is focused on integrating resources post-acquisition of Huazhong Biological to enhance competitive advantages in the poultry vaccine market[82]. Financial Management and Risks - The company has identified potential risks, including a 10% increase in accounts receivable, which may impact cash flow management[5]. - The company has a reasonable provision for bad debts, ensuring sufficient coverage for accounts receivable risks[122]. - The company has a total of RMB 520 million in accounts receivable at the end of the reporting period, which poses a risk to short-term cash flow[122]. - The company is focusing on enhancing its talent acquisition and retention strategies to address human resource risks[122]. Shareholder and Equity Information - The company completed a share repurchase plan, acquiring 9,528,401 shares, approximately 2.36% of the total share capital, at a total cost of RMB 100.45 million[82]. - The company reported a total of 404,493,463 shares outstanding, with 170,224,117 shares under limited sale conditions, representing 42.08% of the total[167]. - Major shareholder Li Shoujun holds 42.65% of the shares, totaling 172,529,411, with 43,132,353 shares pledged[178]. - The company has approved an employee stock ownership plan with a total fundraising amount not exceeding 111.6 million yuan, with a subscription price of 15.07 yuan per share[133]. Environmental and Social Responsibility - The company has completed all pollution control facilities, which are operating normally, and has no significant environmental incidents reported[157]. - The company has not initiated any targeted poverty alleviation work during the reporting period and has no subsequent plans[158]. - The company has not disclosed any other environmental information that requires public disclosure[158].

Financial Performance - Total revenue for Q1 2019 was CNY 307,416,956.41, an increase of 4.40% compared to CNY 294,461,347.53 in the same period last year[8]. - Net profit attributable to shareholders was CNY 43,292,442.26, representing a growth of 12.48% from CNY 38,489,899.87 year-on-year[8]. - Net profit excluding non-recurring gains and losses was CNY 39,678,840.51, up 13.09% from CNY 35,086,542.60 in the previous year[8]. - Basic earnings per share increased to CNY 0.1076, a rise of 13.03% compared to CNY 0.0952 in the same quarter last year[8]. - The total profit for the period was CNY 60.64 million, an increase of 17.64% compared to the previous year[28]. - The company reported a net profit of CNY 50,422,232.88 for Q1 2019, compared to CNY 42,299,699.86 in Q1 2018, representing an increase of 19.3%[87]. - The net profit for the current period is CNY 52,045,494.64, compared to CNY 45,157,644.60 in the previous period, indicating an increase of about 15.5%[92]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,092,092,458.13, reflecting a 3.12% increase from CNY 2,998,445,848.76 at the end of the previous year[8]. - The total liabilities increased to CNY 879,393,024.37 from CNY 744,032,870.06, marking an increase of about 18.2%[73]. - The company's total assets reached CNY 3,092,092,458.13, compared to CNY 2,998,445,848.76 in the previous period, showing a growth of approximately 3.1%[70]. - The total equity attributable to shareholders was CNY 1,969,486,666.51, down from CNY 2,010,171,830.02, indicating a decrease of about 2.0%[76]. - The company's equity decreased to CNY 1,753,114,444.90 from CNY 1,829,070,218.13, a decline of 4.2%[86]. Cash Flow - The net cash flow from operating activities was negative CNY 20,884,585.11, worsening by 57.95% compared to negative CNY 13,222,309.01 in the same period last year[8]. - Cash inflows from investment activities reached ¥431,155,994.93, compared to ¥295,525,141.76 previously, marking an increase of approximately 46%[104]. - The ending cash and cash equivalents balance was ¥241,291,730.34, up from ¥127,058,712.50, reflecting a substantial increase[107]. - Operating cash inflows totaled ¥272,899,658.41, an increase from ¥235,939,827.98 in the previous period, representing a growth of approximately 15.3%[104]. - The net cash flow from financing activities was ¥57,475,440.53, a recovery from -¥71,110,811.14 in the prior period[107]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,299[14]. - The largest shareholder, Li Shoujun, held 42.65% of the shares, amounting to 172,529,411 shares[14]. - The company repurchased a total of 8,090,801 shares, accounting for 2.00% of the total share capital, with a total payment of approximately ¥83.45 million[33]. Research and Development - The company has developed over 280 animal products across various fields, including nearly 170 chemical drugs and over 60 biological products[28]. - The company achieved multiple R&D results, including 2 invention patents and 5 veterinary product approval numbers during the reporting period[29]. - The recombinant avian influenza virus (H5+H7) trivalent inactivated vaccine received production approval in Q1 2019, addressing current challenges in avian influenza prevention[29]. - The company launched several new products, including a pet-specific ear drop solution and an antifungal skin cream, enhancing its product portfolio[29]. - The company is currently in the residue method confirmation stage for its new veterinary drug, which is aimed at addressing antibiotic resistance issues in clinical veterinary practices[38]. Market Strategy - The company is enhancing its marketing services by leveraging internet channels to transition from a manufacturer to a service provider[29]. - The company’s sales strategy includes direct sales to large customers, a dealer network, and government tender procurement[32]. - The company is integrating marketing resources to provide systematic breeding solutions, thereby increasing customer value[32]. - The company is actively expanding its market presence through the development of innovative products and strategic partnerships in the veterinary medicine industry[39]. Investment and Acquisitions - The company plans to expand its market presence through acquisitions, including the acquisition of Huazhong Biopharmaceutical Co., Ltd.[49]. - The company completed the acquisition of equity in Huazhong Biopharmaceutical Co., Ltd., with a total investment of ¥12,400.00 million[49]. - The company completed the acquisition of a 33.34% stake in Tianjin Sairui Duopeptide Technology Co., Ltd. for 1,000.00 million RMB, increasing its ownership to 66.67%[55].

Financial Performance - The company reported a profit distribution plan of 1.50 CNY per 10 shares (including tax) based on a total of 404,493,463 shares[6]. - The company's operating revenue for 2018 was ¥1,189,866,012.40, representing a year-over-year increase of 13.61% compared to ¥1,047,334,488.89 in 2017[25]. - The net profit attributable to shareholders for 2018 was ¥118,978,853.68, which is a 13.43% increase from ¥104,895,236.66 in 2017[25]. - The net profit after deducting non-recurring gains and losses was ¥100,504,372.87, showing a growth of 24.82% from ¥80,519,229.96 in 2017[25]. - The net cash flow from operating activities for 2018 was ¥174,881,770.06, a significant increase of 59.17% compared to ¥109,873,523.30 in 2017[25]. - The total assets at the end of 2018 amounted to ¥2,998,445,848.76, reflecting a 2.54% increase from ¥2,924,214,309.69 at the end of 2017[25]. - The net assets attributable to shareholders at the end of 2018 were ¥2,010,171,830.02, which is a 2.99% increase from ¥1,951,866,995.79 at the end of 2017[25]. - The basic earnings per share for 2018 was ¥0.2941, up 13.42% from ¥0.2593 in 2017[25]. - The diluted earnings per share for 2018 also stood at ¥0.2941, reflecting the same growth rate of 13.42% compared to ¥0.2593 in 2017[25]. - The weighted average return on equity for 2018 was 6.02%, an increase from 5.46% in 2017[25]. - The total profit amounted to CNY 161.95 million, an increase of 12.09% compared to the previous year[64]. - The net profit attributable to shareholders reached CNY 118.98 million, up by 13.43% year-on-year[64]. - The cash dividend for 2018 accounted for 51.00% of the net profit attributable to ordinary shareholders, which was RMB 118,978,853.68[156]. Risks and Challenges - The company faces risks including human resources, product development, and significant accounts receivable[6]. - The regulatory environment for the veterinary drug industry has become stricter, with increased oversight from the Ministry of Agriculture and Rural Affairs[44]. - As of the end of the reporting period, the company's accounts receivable stood at 460 million yuan, which poses a risk to short-term cash flow and increases the likelihood of bad debts[142]. Product Development and Innovation - The company has a professional R&D team of nearly 300 members, primarily with doctoral and master's degrees, maintaining a leading position in the industry[53]. - The company has obtained multiple patents and new veterinary drug registration certificates, including a trivalent inactivated vaccine for avian influenza, which addresses current challenges in virus prevention and control[54]. - The company offers over 280 animal health products, including nearly 170 chemical drugs and over 60 biological products, making it one of the most comprehensive veterinary drug companies in China[54]. - The company is actively pursuing research and development initiatives to innovate and expand its product offerings in the veterinary sector[93]. - The company has developed new veterinary drug products, enhancing its product portfolio and market competitiveness[92]. - The company is focusing on expanding its product offerings in the animal health sector, particularly in the poultry and pet markets[100]. Market Position and Strategy - The company has established a strong industry position, recognized for its comprehensive product range covering disease prevention, diagnosis, treatment, and growth promotion[48]. - The company emphasizes a unified development strategy, focusing on high-quality vaccines and veterinary drugs, while enhancing customer experience through systematic solutions[41]. - The company is committed to innovation and has a proactive approach to market changes, focusing on new product development to mitigate operational risks[48]. - The company aims to leverage its new product registrations to capture a larger market share in the veterinary pharmaceutical industry[93]. - The company is focused on expanding its market reach through strategic partnerships and collaborations in the veterinary sector[93]. Financial Management and Investments - The company has a dedicated investor relations team to handle inquiries and maintain communication with stakeholders[20]. - The company actively engages in capital market activities for financing and mergers to capitalize on industry transformation opportunities[48]. - The company plans to conduct cash distributions annually after the shareholders' meeting, with a minimum cash dividend ratio of 80% for mature companies without major capital expenditure plans[146]. - The company has confirmed that all commitments made during the reporting period have been fulfilled without any violations[166]. - The company plans to use the net proceeds from the private placement to acquire a 38.27% stake in Huanan Biological and to supplement working capital[172]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has declared that all board members attended the meeting to review the report[5]. - The profit distribution plan was approved by the board and complied with the company's articles of association and relevant regulations[157]. - The company has commitments regarding social insurance and housing fund payments, ensuring no financial losses will occur due to employee compensation requirements[163]. - The company has made commitments to avoid related party transactions and ensure strict compliance with financial management and internal control systems[163]. - The company has appointed Xinyong Zhonghe Accounting Firm with an audit fee of 820,000 RMB, and the firm has been providing services for 3 consecutive years[180].

证券代码：300119 证券简称：瑞普生物 公告编号：2019-051 天津瑞普生物技术股份有限公司 关于举行投资者网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天津瑞普生物技术股份有限公司（以下简称"公司"）已于2019年4月18日 发布了2018年年度报告。为便于广大投资者更深入全面地了解公司情况，公司定 于2019年5月9日（星期四）下午15:00-16:30 在全景网举办2018年度天津辖区网 上集体接待日活动。 本次活动将采用网络远程的方式举行，投资者可登录"全景•路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次"天津辖区上市公司网上集体接待日"的人员有：公司董事长、总 经理李守军先生，董事、副总经理、财务总监胡文强先生，董事会秘书徐健女士。 欢迎广大投资者积极参与。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇一九年四月十八日 ...

Financial Performance - Operating revenue for the reporting period was ¥293,408,616.33, representing an 8.36% increase year-on-year, while year-to-date revenue was ¥876,561,704.21, up 17.75%[7] - Net profit attributable to shareholders was ¥37,442,203.33, a decrease of 19.02% compared to the same period last year, with year-to-date net profit at ¥105,944,945.01, an increase of 3.44%[7] - The basic earnings per share for the reporting period was ¥0.0926, a decrease of 18.99% year-on-year, with year-to-date earnings per share at ¥0.2619, an increase of 3.44%[7] - The company reported a total profit of CNY 141,415,255.81 for the current period, compared to CNY 131,399,073.30 in the previous period, an increase of 7.7%[57] - The total comprehensive income for the current period was CNY 123,747,816.28, compared to CNY 114,484,931.36 in the previous period, reflecting an increase of 8.8%[58] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,017,161,313.32, an increase of 3.18% compared to the end of the previous year[7] - Total liabilities stood at 780,045,296.56 yuan, compared to 747,952,355.25 yuan at the start of the period, indicating a rise of approximately 4%[42] - The company's total equity decreased to CNY 1,742,151,542.12 from CNY 1,801,522,972.63 year-over-year[46] - Cash and cash equivalents decreased to 310,009,603.90 yuan from 397,802,898.85 yuan, reflecting a decline of approximately 22%[40] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥81,262,992.57, an increase of 127.84%[7] - Operating cash flow for the period was CNY 81,262,992.57, compared to CNY 35,667,159.37 in the previous year, indicating an increase of approximately 128.5%[62] - The company reported a net cash outflow from investment activities of CNY -88,051,947.01, compared to CNY -14,039,695.98 in the previous year, indicating a worsening investment cash flow situation[64] - The net cash flow from financing activities was -72,910,837.82 CNY, compared to a positive net cash flow of 72,477,229.92 CNY in the previous year[68] Research and Development - The company obtained several new patents during the reporting period, including a method for preparing a pig fever vaccine and a herbal composition for treating equine colic[19] - The company has ongoing research projects, although specific details on progress and impact were not provided in the report[19] - Research and development expenses for Q3 2018 were CNY 19,015,519.91, slightly down from CNY 19,631,240.97 in Q3 2017[47] - The company is in the process of refining clinical trial application materials for several new products, indicating ongoing research and development efforts[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,630[11] - The largest shareholder, Li Shoujun, holds 42.65% of the shares, amounting to 172,529,411 shares, with 129,397,058 shares pledged[11] - The company has committed to fulfilling its obligations regarding employee social insurance and housing fund contributions, ensuring compliance with legal requirements[23] Compliance and Governance - The company has not reported any violations of commitments made by its actual controller and shareholders during the reporting period[23] - The company reported a commitment to avoid any financial losses due to related party transactions and fund occupation, ensuring compliance with financial management and internal control systems[24] - The company has reiterated its commitment to comply with relevant regulations regarding the issuance and underwriting of securities, ensuring no violations occur during the private placement of shares[25] Dividend Policy - The company has a stable and continuous profit distribution policy, prioritizing cash dividends[30] - Cash dividends will be distributed only if the audited net profit is positive and cash flow is sufficient, without affecting the company's ongoing operations[31] - The company approved a cash dividend of 1.50 yuan per 10 shares, totaling approximately 606.74 million yuan based on 404,493,463 shares[34] Product Development - The company has enriched its new veterinary drug portfolio with the introduction of Astragalus and Five-Leaf Ginseng granules, enhancing its competitiveness in the Chinese veterinary medicine sector[20] - The company has successfully launched Ivermectin tablets for pets, expanding its product line in the pet clinical parasitic spectrum[20] - The company is developing a bivalent inactivated vaccine for H5 and H7 avian influenza viruses, which is anticipated to effectively protect against current circulating strains[21]

Financial Performance - Total revenue for the first half of 2018 reached ¥583,153,087.88, representing a 23.12% increase compared to ¥473,652,889.56 in the same period last year[18]. - Net profit attributable to shareholders was ¥68,502,741.68, up 21.92% from ¥56,186,354.00 year-on-year[18]. - Net profit after deducting non-recurring gains and losses increased by 35.42%, totaling ¥61,222,183.59 compared to ¥45,208,105.38 in the previous year[18]. - Basic earnings per share rose to ¥0.1694, reflecting a 21.96% increase from ¥0.1389 in the previous year[18]. - Total profit reached 94.06 million yuan, up 22.83% year-on-year, while net profit attributable to shareholders was 68.50 million yuan, reflecting a growth of 21.92% compared to the previous year[42]. - The company achieved operating revenue of 583.15 million yuan, a year-on-year increase of 23.12%, primarily driven by significant growth in veterinary drug sales[42]. - The company reported a total operating cost of CNY 508,566,370.44, which is an increase of 20.7% from CNY 421,071,018.47 in the first half of 2017[151]. - The company reported a total of 70,839.38 million RMB in raised funds, with 364.11 million RMB still unallocated as of June 30, 2018[67]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥35,912,218.76, a 371.63% increase from a negative cash flow of ¥13,221,104.49 in the same period last year[18]. - The total assets at the end of the reporting period were ¥2,851,599,276.64, a decrease of 2.48% from ¥2,924,214,309.69 at the end of the previous year[18]. - The company's accounts receivable at the end of the reporting period amounted to 496 million yuan, which poses a risk to short-term cash flow and increases the likelihood of bad debts[79]. - The ending balance of cash and cash equivalents was ¥256,578,773.01, an increase from ¥145,689,824.77 in the previous period[160]. - The total liabilities decreased to CNY 656,994,778.84 from CNY 747,952,355.25, a reduction of approximately 12.1%[143]. Research and Development - The company aims to enhance its R&D capabilities and has established a dedicated pet medicine division, focusing on high-quality and high-value animal health products[30]. - The company continues to invest in R&D to develop efficient, high-quality, safe, and environmentally friendly animal health products[30]. - The company has developed a revolutionary avian influenza DNA vaccine, addressing global challenges in vaccine development speed and effectiveness[36]. - The company has completed clinical trials for several new vaccines, including inactivated vaccines for H7N9 and H5N2 avian influenza viruses, which are expected to enhance product competitiveness[50]. - The company is focusing on the development of a heat-resistant live vaccine for preventing pseudorabies in pigs, which represents an upgrade to existing products[49]. Market Strategy and Operations - The marketing strategy emphasizes transitioning from product sales to service-oriented solutions, enhancing customer value propositions through systematic solutions and rapid response[31]. - The company plans to accelerate the launch and promotion of key vaccine products such as Youruikang and Xinfakang, targeting new growth drivers in the market[31]. - The company is leveraging the "Internet+" initiative to integrate online and offline resources, enhancing the efficiency of animal disease diagnosis and treatment through the "Yangzhi Bao" platform[31]. - The company has improved operational efficiency and risk management through standardized operations and enhanced organizational management[27]. - The company is transitioning from a product provider to a comprehensive service and solution supplier, driven by the rapid expansion of large-scale farming enterprises[41]. Investment and Financing - The company is actively utilizing capital markets to raise funds and strengthen its capital structure, aiming to enhance overall competitiveness[32]. - The company plans to use the net proceeds from the private placement to acquire a 38.27% stake in Huanan Biological and to supplement working capital[94]. - The company has committed to strictly manage the raised funds according to relevant regulations and its own fundraising management measures[94]. - The company has allocated 9,610.64 million CNY for working capital, with a utilization rate of 100.09%[66]. - The company has a total of 57,278.6 million CNY committed to investment projects, with 79,751.5 million CNY already invested[66]. Risks and Challenges - The company acknowledges risks related to human resources, product development, and accounts receivable, urging investors to be cautious[4]. - The company has implemented a reasonable provision for bad debts based on the aging structure of accounts receivable, ensuring sufficient provisioning[79]. - The company has faced challenges in the long and uncertain research and development cycle of veterinary drug products, which require regulatory approvals before production[78]. - The company is actively expanding its market presence while adhering to a cautious credit policy in response to changing market conditions[79]. Corporate Governance and Shareholder Information - The company did not undergo any changes in its board of directors, supervisors, or senior management during the reporting period[134]. - The company has not disposed of any major assets or equity during the reporting period[74]. - The largest shareholder, Li Shoujun, holds 42.65% of the shares, amounting to 56,825,000 shares, which are currently pledged[126]. - The company has a total of 16,913 shareholders at the end of the reporting period[126]. - The company’s employee stock ownership plan will participate in the subscription of the private placement shares[92].